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ABSTRACT
Background: Venous thrombotic events (VTE) occur at high rates in HIV/AIDS patients 
and are likely under-diagnosed in rural sub-Saharan Africa.
Objective: To describe clinical presentations and challenges in the management of 
VTE in patients with advanced HIV/AIDS.
Design: Case series from patients enrolled in a prospective observational cohort study. 
Settings: A clinical research centre in rural Kericho, Kenya. 
Subjects: Two hundred patients with median age 38 (30-47) years, BMI 16.9 (12.4-20.3) 
kg/m2, haemoglobin 9.3 (6.8-13.4) g/dL, CD4+ T-cell count 27 (4-77) cells/mm3 and 
plasma HIV RNA 5.23 (3.70-5.88) log10copies/mL.
Interventions: VTE cases were diagnosed by clinical presentation and Doppler/
radiographic confirmation. Anti-coagulation therapy was managed by a 
multidisciplinary team; patients were initiated on enoxaparin or heparin followed 
by warfarin.
Results: Over two years, 11 patients (5.5%) experienced VTE. All but one (10/11, 90.9%) 
case occurred within six months of starting ART. Nine patients had peripheral VTE (five 
popliteal, four femoral) and two had cerebral sinus thromboses. VTE was diagnosed 52 
(1-469) days after ART initiation, and 81.8% of cases were outpatients at presentation.  
All patients received at least one concomitant medication that could significantly  
interact with warfarin (efavirenz, nevirapine, lopinavir/ritonavir, rifampicin, 
trimethoprim-sulfamethoxazole, and fluconazole). A median of 39 (10-180) days and 
eight (4-22) additional clinic visits were required to achieve/maintain a therapeutic 
INR of 2-3. Two minor bleeding complications occurred. No recurrent VTE cases were 
observed. 
Conclusion: Consideration of VTE and preparedness for management in patients 
with advanced HIV/AIDS starting ART is critical in sub-Saharan Africa. Overcoming 
challenges in anti-coagulation is possible in rural settings using a multidisciplinary 
team approach.
INTRODUCTION
Venous thrombotic events (VTE), most commonly 
deep venous thrombosis (DVT) and pulmonary 
embolism (PE) but to a lesser extent cerebral sinus 
thromboses, occur at higher rates in HIV/AIDS 
patients than in the general population (1-3). A 
hyper-coagulable state in advanced HIV/AIDS 
patients has been postulated as a risk factor for VTE 
(4). Studies have associated the hyper-coagulable 
state in these patients with abnormalities in the 
coagulation cascade. These include the presence of 
lupus anti-coagulant and anticardiolipin antibodies; 
increased levels of von Willebrand factor, fibrinogen, 
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and d-dimer; and, deficiencies of protein C, protein 
S, antithrombin III and heparin co-factor II (4, 5, 6). 
These abnormalities correlate with the severity of 
HIV-associated immunodeficiency (4). In rural sub-
Saharan Africa, a region with the highest burden of 
HIV/AIDS, VTE is likely under diagnosed due to a 
low index of suspicion and lack of diagnostic tools (e.g. 
ultrasonography, computerised tomography (CT), 
and magnetic resonance imaging (MRI]).  Untreated 
VTE may be an underappreciated factor leading to 
early morbidity and mortality in advanced HIV/
AIDS patients in sub-Saharan Africa. 
 Oral anti-coagulation therapy with warfarin 
is the mainstay of VTE management (7). Safe and 
effective warfarin use is challenging due to its 
narrow therapeutic index, numerous medication and 
food interactions, and need for frequent laboratory 
monitoring (8-10). The challenge is further magnified 
in patients with advanced HIV/AIDS and VTE who 
require complex pharmacotherapy including ART 
and comorbid opportunistic infections prophylaxis 
and treatment (11). Warfarin drug interactions 
are well described with ART and HIV/AIDS-
related medications including non-nucleosides 
reverse transcriptase inhibitors (NNRTI), (12-14) 
protease inhibitors (PI), (14-16) rifampicin, (17) and 
antimicrobial agents such as cotrimoxazole, (10,18) 
presenting numerous challenges in safely achieving 
and maintaining the desired international normalised 
ratio (INR) of 2-3. 
 Healthcare workers including doctors, clinical 
officers, nurses, and pharmacists in rural sub-
Saharan Africa may have inadequate radiographic 
and laboratory resources and clinical experience to 
diagnose VTE and optimally manage anti-coagulation 
therapy. We present a case series of 11 patients 
with advanced HIV/AIDS who started ART and 
subsequently experienced VTE with emphasis on 
challenges and lessons learned in achieving and 
maintaining therapeutic warfarin anti-coagulation.
MATERIALS AND METHODS
The patients described in this case series were 
enrolled in the Immune Reconstitution Inflammatory 
Syndrome (IRIS) study (19). Conducted between 
February 2009 and April 2012, the IRIS study was a two 
year, prospective observational cohort study of ART-
naive HIV-positive patients with CD4+ T cell count 
<100/mm3 who initiated Kenya Ministry of Health 
(MoH) recommended ART. Kenya MoH first line ART 
consists of one non-nucleoside reverse transcriptase 
inhibitor (NNRTI) plus two nucleoside reverse or 
transcriptase inhibitors (NRTI) ( 20,21). Opportunistic 
infections and other illnesses were managed 
according to the local standard of care (22). 
Hospitalised patients who were immobile or had 
additional risk factors for VTE were prescribed 
subcutaneous enoxaparin or heparin. The study 
was approved by the Kenya Medical Research 
Institute (KEMRI), US Uniformed Services University 
Infectious Disease (USU ID), and the US National 
Institute of Allergy and Infectious Diseases (NIAID) 
Institutional Review Boards.  All patients provided 
written informed consent.
 The KEMRI/Walter Reed Project (WRP) Clinical 
Research Centre (CRC) is located on the grounds of 
Kericho District Hospital; a MoH facility providing 
care to a rural, largely uninsured population 
(23). Kericho is located among the tea fields and 
plantations of Kenya’s southern Rift Valley Province 
260 kilometres northwest of Nairobi. The KEMRI/
WRP CRC conducts HIV-1 vaccine, therapeutics, and 
health economics research as part of the US Military 
HIV Research Programme (MHRP) and includes a 
College of American Pathologists (CAP) accredited 
lab (24,25).  The MoH in collaboration with KEMRI/
WRP supports HIV care, prevention, and treatment 
services largely under the President’s Emergency 
Plan for AIDS Relief (PEPFAR) program in Kericho 
and throughout the southern Rift Valley Province of 
Kenya (population of approximately 2.5 million) (26). 
Patients presenting with signs and symptoms 
consistent with VTE had confirmatory testing by 
Doppler ultrasonography and CT and/or MRI 
scans as indicated (7). A multidisciplinary approach 
was adapted for management of anti-coagulation 
therapy.  Physicians and pharmacists provided 
staff education on warfarin dosing, monitoring 
and dosage modification, assessment of drug-drug 
interactions, and patient counselling. Nurses, clinical 
officers and a nutritionist who is also a social worker 
participated in the comprehensive care of patients.   A 
dedicated pharmacist identified potential drug-drug 
interactions, provided patient counselling on warfarin 
use, and monitored patients’ medication and dietary 
history. The multidisciplinary team reviewed and 
implemented appropriate dosing adjustments based 
upon clinical and laboratory data.  
 Following VTE diagnosis, those seen in the 
outpatient clinic were hospitalised.   Subcutaneous 
enoxaparin or heparin was started followed by oral 
warfarin (Marevan, Goldshield Pharmaceuticals, 
UK). INR values were checked at baseline and 1-3 day 
intervals until a therapeutic INR (2-3) was achieved, 
(27) when enoxaparin was stopped. If clinically 
appropriate, patients were discharged. INR was then 
monitored every five days.  Once a stable therapeutic 
INR (two consecutive values of 2-3) was obtained, 
patients were monitored monthly or as clinically 
indicated. Warfarin dose adjustments were made in 
1-2.5 mg increments based upon INR results.  For an 
INR >5, warfarin was held until the INR returned to 
the therapeutic range. Additional monitoring and 
dosage adjustments occurred as indicated and based 
upon clinical scenarios (e.g. epistaxis, initiation of 
Mycobacterium tuberculosis (Tb) therapy).   
De-identified data for this case series were extracted 
from study case report forms and complied on MS 
Excel worksheets.  Simple statistics (n, [%] or median 
[range]) were used in describing characteristics of 
the case series. 
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RESULTS
Among 200 patients enrolled in the IRIS study and 
started ART, 11 (5.5%) cases of VTE were diagnosed 
(Table 1). All but one (10/11, 90.9%) VTE case occurred 
within six months of starting ART. Overall, patients 
comprising the case series were predominantly female 
(63.4%) aged 38 years (30-47) with median CD4+ 
T-cell count of 27 (4-77) cells/mm3. Ten patients were 
receiving first line ART consisting of zidovudine 
or stavudine with lamivudine, plus efavirenz or 
nevirapine. One patient was receiving second line 
ART (zidovudine, lamivudine, and lopinavir/
ritonavir) at the time of VTE diagnosis. Five patients 
had comorbid pulmonary Tb, and two had central 
nervous system (CNS) infections with altered mental 
status (one with cryptococcal meningitis and cerebral 
toxoplasmosis, the other patient with progressive 
multifocal leucoencephalopathy [PML]). Overall, 
the patients were underweight or malnourished 
(median body mass index 16.9 (range 12.4-20.3) 
kg/m2), had hypoproteinemia (median albumin 2.8 
(range 2.0-3.7) g/dL), and had signs of inflammation 
(median erythrocyte sedimentation rate 73 (range 
10-132) mm/h).
Table 1


























2 47 F 4 5.23 18.7 2.64 8 110 EFV/d4T/3TC Pulmonary Tb
3 38 F 60 3.70 18.5 3.63 12.9 10 EFV/ZDV/3TC None
4 39 F 77 5.37 16.8 2.01 9.9 104 EFV/d4T/3TC Pulmonary Tb
5 31 M 27 5.88 16.1 2.40 9.1 73 EFV/d4T/3TC Pulmonary Tb
6 40 F 56 4.98 16.9 2.78 7.3 132 NVP/d4T/3TC Genital herpes
7 38 F 32 5.73 13.7 2.15 6.8 58 EFV/d4T/3TC Pulmonary Tb
8 36 F 15 5.58 17.8 3.26 9 84 EFV/d4T/3TC Bacterial 
pneumonia
9 35 F 30 4.92 12.4 2.20 10 65 EFV/d4T/3TC Oral 
candidiasis






11 37 M 13 5.08 20.3 3.74 13.4 13 NVP/
ZDV/3TC
Genital herpes










Median 38 27 5.23 16.9 2.78 9.3 73
ART = antiretroviral therapy, 3TC = lamivudine, d4T = stavudine, EFV = efavirenz, LPV/r = lopinavir/
ritonavir, NVP = nevirapine, ZDV = zidovudine
BMI = body mass index, ESR = erythrocyte sedimentation rate, F = female, M = male, Hgb = haemoglobin, 
Tb = tuberculosis
VTE diagnoses were made a median of 52 (1-469) days 
after ART initiation.  All but one VTE occurred in the 
first six months (Table 2). Nine (81.8%) VTE diagnoses 
were made at the outpatient setting, three of whom 
had previous hospitalisations with discharge dates 
four to 42 days before VTE diagnoses. Two patients 
had cerebral sinus thrombosis:  one with transverse 
sinus thrombosis and the other with both carvernous 
and transverse sinus thromboses. Both patients 
presented with neurologic symptoms (psychosis, 
seizure, and headache) that prompted CNS imaging. 
One patient had a concurrent AIDS-associated CNS 
infection (PML). Peripheral VTE was diagnosed in 
nine patients, five patients with popliteal VTE and 
four with femoral VTE.  
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Table 2
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Range 1 - 469 13-197
DVT = deep vein thrombosis, PE = pulmonary embolism, VTE = venous thrombotic event
ART = antiretroviral therapy, 3TC = lamivudine, d4T = stavudine, EFV = efavirenz, LPV/r = lopinavir/
ritonavir, NVP = nevirapine, ZDV = zidovudine
Dx = diagnosis, Outpt = outpatient, f/u = follow-up
* No f/u = no follow-up CD4 or HIV RNA since pre-ART evaluation; both patients died (see text for further 
discussion)
Two patients died. One patient with PML died four 
months after VTE due to complications of PML. 
Another patient with femoral VTE died seven days 
after admission. This patient was hospitalised with 
left leg swelling and difficulty in walking. She was 
cachechtic, had oral candidiasis and was treated for 
probable cellulitis before femoral VTE was diagnosed 
and managed. Pulmonary embolism (PE) was found 
at autopsy and was considered the cause of death. 
The remaining nine patients completed warfarin 
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therapy with a treatment duration between six and 
ten months. 
Warfarin dosing, INR values, drug interactions, and 
other clinical considerations warrant attention (Table 
3).  Warfarin drug-drug interactions were frequent. 
In addition to ART, all patients received either 
trimethoprim-sulfamethoxazole (enhanced warfarin 
effect) or dapsone for prophylaxis of opportunistic 
infections (OI) (e.g. Pneumocystis jirovecii, malaria, 
and diarrheal infections [for trimethoprim-
sulfamethoxazole only]) and multivitamin. A notable 
number of patients (n=7) also received additional 
medications with potential drug interactions 
including rifampicin-based Tb treatment (n=5) 
(diminished warfarin effect) and fluconazole 
prophylaxis (n=1) (enhanced warfarin effect) for 
cryptococcal meningitis. 
Table 3
































2 7.5 EFV ↑ 7.5 13 12 58.3
RFP ↓
T-S ↑
3 5 EFV ↑ 7.5 6 10 66.7
T-S ↑
4 5 EFV ↑ 7.5 10 60 37.5
RFP ↓
T-S ↑
5 7.5 EFV ↑ 2.5 7 60 22.2
RFP ↓
T-S ↑
6 5 NVP ↓ 10 16 50 47.3
Doxy ↑
7 5 EFV ↑ 7.5 11 10 40
RFP ↓
T-S ↑
8 5 EFV ↑ 10 7 20 42.9
9 2.5 EFV ↑ 2.5 6 n/a(death) n/a(death)
T-S ↑
10 7.5 LPV/r ↓ 10 48 48 11
T-S ↑
11 5 NVP ↓ 12.5 180 9.4
T-S ↑
Median 5 7.5 10.5 39 38.75
Range 2.5-7.5 2.5-12.5 6-48 10-180 9.4-66.7
1. Stable therapeutic INR was defined as two consecutive INR of 2-3 
2. Proportion of visits with INR of 2-3 while on warfarin (number of results with INR of 2-3 divided by total 
number of INR results multiplied by 100%)
INR=International Normalized Ratio, Doxy=doxycycline, EFV=efavirenz, FLU=fluconazole, LPV/r=lopinavir/
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ritonavir, NVP=nevirapine, RFP=Rifampicin, 
T-S=trimethoprim-sulfamethoxazole,.
The median warfarin starting dose was 5.0 (2.5-7.5) 
mg, and the median final dose was 7.5 (2.5-12.5) mg. 
All patients required warfarin dose adjustments in 
order to achieve and maintain a therapeutic INR of 
2-3. Of all the INR readings obtained during follow-
up, 38.8% (9.4%-66.7%) fell within the therapeutic 
range of 2-3. Patients required eight (4-22) extra 
clinic visits for warfarin monitoring. Two patients 
reported transient bleeding complications: one with 
haematuria (warfarin dose 7.5 mg, INR=10); and, one 
with recurrent epistaxis (warfarin dose 5 mg with an 
INR=2.0 and 12.5 mg with an INR=1.1). 
DISCUSSION
We found in our research clinic in rural Kericho 
Kenya a high proportion of VTE in patients with 
advanced HIV/AIDS, most notably during the 
first six months of ART. VTE management posed 
additional challenges and burden on the clinical 
research team caring for these ill patients. The 
majority of patients were ambulatory at presentation 
and without traditional risks factors for VTE such 
as stasis, trauma, or known hypercoagulability (e.g. 
malignancy), beyond HIV. All the patients’ anti-
coagulation management was complicated by drug-
drug interactions with medications used for treatment 
of HIV or opportunistic infections.  In our clinic, using 
a multidisciplinary team approach, competency in 
warfarin management quickly improved after the 
diagnosis of the first few cases of VTE.  Since the 
clinic team also managed the hospitalized patients, 
attention to VTE prophylaxis with enoxaparin or 
heparin increased for at risk patients, which likely 
prevented subsequent in- and outpatient VTE. 
 In this patient population, achieving and/or 
maintaining a therapeutic INR of 2-3 was a challenge. 
Periods of sub- or supra-therapeutic anti-coagulation 
pose risks to patients. Fortunately, there were no 
recurrent VTE. Warfarin was well tolerated overall 
with transient, non-serious bleeding complications 
(epistaxis and haematuria) in two patients. Some 
ART and drugs used for treatment or prevention of 
OI significantly interfered with warfarin metabolism 
or biosynthesis of vitamin-K dependent coagulation 
factors (10, 28) making it difficult to predict the 
warfarin dose required to achieve therapeutic INR. 
 Some patients received multiple cytochrome 
P450 enzyme inducing and inhibiting medications 
(e.g. efavirenz, rifampicin, and fluconazole) 
concomitantly, making it even more challenging to 
anticipate the net inhibitory or induction outcome. 
Adherence to ART, OI medications, and warfarin 
posed further challenges in successfully achieving 
anti-coagulation. In addition, alterations in routine 
dietary consumption of vitamin-K rich food products 
in this patient population may also have contributed 
to the INR fluctuations.  Rivaroxaban, an oral factor Xa 
inhibitor, non-coumarin anti-coagulant, which does 
not require INR monitoring, is being recommended 
for treatment and prevention of VTE in resource rich 
settings (29).  However, being a CYP3A4 substrate 
with potential for interactions with drugs used for 
OI such as rifampicin, the optimal dosing in patients 
receiving other CYP3A4 inducers or inhibitors is 
not known.  Moreover, the cost of such therapy is 
prohibitive in our setting and most likely in most of 
sub-Saharan Africa.
 Comparing to similar analyses of HIV and VTE, 
our prevalence (5.5%) was slightly higher than two 
US-based cohorts (2.8% and 3.7%) (2,4).  This is likely 
reflective of our cohort representing patients with 
more advanced HIV and notably  lower CD4+ T-cell 
counts.  A similarity in the three cohorts was the 
occurrence of VTE in a relatively young population, 
which is in contrast to traditional risk factor of VTE 
in the HIV uninfected, which is more likely seen in 
older adults. Finally, a recent publication from an 
academic tertiary referral hospital in Kenya (30) 
reported a slightly higher time in therapeutic range 
of INR than in our series (47.0% vs. 38.8%).  However, 
only a quarter of the patients had HIV and with less 
advanced disease.
 Strengths of our case series include our study 
was prospective with close clinical follow-up using 
a CAP accredited laboratory assuring quality results. 
Additionally in contrast to data generated from urban 
and/or academic settings, ours is rural in nature and 
representative of where the majority of HIV burden is 
found in Kenya and sub-Saharan Africa.  Limitations 
inherent to case series with a relatively small number 
of events must be recognised.  However, the clinical 
significance of even low prevalence events warrants 
attention.  Finally, resources available at our CRC 
are likely not available throughout rural Kenya and 
sub-Saharan Africa.  Therefore, the results may not be 
directly generalizeable to all settings, but education 
and increased awareness are broadly available.  
 In conclusion, VTE is likely an under recognised 
problem leading to early morbidity and mortality in 
advanced HIV/AIDS patients initiating ART in rural 
Kenya and sub-Saharan Africa. Managing warfarin 
therapy in these patients is labour intensive and adds 
to inherent challenges in managing patients with 
advanced HIV/AIDS.  Consideration of VTE and 
preparedness for warfarin management in patients 
with advanced HIV/AIDS starting ART will be critical 
for optimizing outcomes.  Overcoming challenges in 
VTE diagnosis and anti-coagulation management is 
possible in rural settings with a vigilant and educated 
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multidisciplinary team.
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